IRST-AUSL Romagna breast cancer Conference: From molecular signature to clinical oncology
19.06.2025
CCCRN - Comprehensive Cancer Care and Research Network
Rimini, 19-20 giugno 2025
Centro Congressi SGR
Scarica il Programma in PDF
Ruoli e responsabilità degli attori della ricerca clinica: gestione, conduzione e monitoraggio di uno studio clinico
07.05.2025
7 maggio - 28 maggio 2025 - 11 giugno 2025
FAD WEBINAR
Responsabile scientifico: Antonino Musolino
Scarica il Programma in PDF
Empowering talks: state of the art and translational research in Breast and Ovarian Cancer
04.04.2025
4 aprile 2025
Star Hotel du Parc
Parma
Scarica il Programma in PDF
L’evoluzione della medicina di precisione e personalizzata in oncologia: il ruolo della ricerca clinica accademica
28.03.2025
28-29 marzo 2025
HOTEL NH BOLOGNA DE LA GARE
Bologna
Scarica il Programma in PDF
Impact of edoxaban-related adverse events in patients with cancer experiencing venous thromboembolism during antineoplastic therapy: Results of the phase IV EDOI study (GOIRC-05–2018)
09.02.2025
Scarica il documento in PDF
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line
13.01.2025
Scarica il documento in PDF
Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
13.01.2025
Scarica il documento in PDF
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years’ Follow-Up
09.01.2025
Scarica il documento in PDF
Adjuvant Pertuzumab and Trastuzumab in EarlyHuman Epidermal Growth Factor Receptor 2-PositiveBreast Cancer in the APHINITY Trial: Third InterimOverall Survival Analysis With Efficacy Update
08.01.2025
Scarica il documento in PDF
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study
07.01.2025
Scarica il documento in PDF